King’s Spin-out Targets Human Trials for Oral Cancer Drug After Promising Mouse Results

Researchers plan to begin human trials in about two years after mouse studies demonstrated that the oral inhibitor restored chemotherapy sensitivity by blocking macrophage HO-1.